Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma

BACKGROUND: Histological transformation to diffuse large B-cell lymphoma (tDLBCL) occurs in a significant proportion of indolent lymphomas. However, few studies of novel agents inform its management, particularly when relapsed after or refractory (R/R) to prior treatment. PATIENTS AND METHODS: We pr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Lymphoma Myeloma Leuk
Hlavní autoři: Graf, Solomon A., Cassaday, Ryan D., Morris, Karolyn, Voutsinas, Jenna M., Wu, Qian Vicky, Behnia, Sanaz, Lynch, Ryan C., Krakow, Elizabeth, Rasmussen, Heather, Chauncey, Thomas R., Kanan, Sandra, Soma, Lorinda, Smith, Stephen D., Gopal, Ajay K.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904587/
https://ncbi.nlm.nih.gov/pubmed/33358575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2020.11.023
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky